Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2009

01-06-2009 | Special Article

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

Authors: Joan Albanell, Xavier Andreu, María José Calasanz, Ángel Concha, José María Corominas, Tomás García-Caballero, José Antonio López, Fernando López-Ríos, Santiago Ramón y Cajal, Francisco J. Vera-Sempere, Ramón Colomer, Miguel Martín, Emilio Alba, Antonio González-Martín, Antonio Llombart, Ana Lluch, José Palacios

Published in: Clinical and Translational Oncology | Issue 6/2009

Login to get access
Metadata
Title
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Authors
Joan Albanell
Xavier Andreu
María José Calasanz
Ángel Concha
José María Corominas
Tomás García-Caballero
José Antonio López
Fernando López-Ríos
Santiago Ramón y Cajal
Francisco J. Vera-Sempere
Ramón Colomer
Miguel Martín
Emilio Alba
Antonio González-Martín
Antonio Llombart
Ana Lluch
José Palacios
Publication date
01-06-2009
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2009
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-009-0370-6

Other articles of this Issue 6/2009

Clinical and Translational Oncology 6/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine